Progression of paclitaxel-induced neuropathy following discontinuation of treatment

Muscle and Nerve

Volumn 20, Issue 6, 1997, Pages 750-752

  Van Den Bent, Martin J ^a   Van Raaij Van Den Aarssen, Vivian J M ^a   Verweij, Jaap ^a   Doorn, Pieter A V ^a   Smitt, Peter A E Sillevis ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

diabetes mellitus; neurotoxicity; paclitaxel induced neuropathy

Indexed keywords

PACLITAXEL;

AGED; AREFLEXIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; HYPESTHESIA; PARESTHESIA; PRIORITY JOURNAL; SENSORIMOTOR NEUROPATHY;

AGED; FEMALE; HUMANS; NEURAL CONDUCTION; NEURONS, AFFERENT; NEUROTOXINS; PACLITAXEL;

EID: 0030910759     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(199706)20:6<750::AID-MUS15>3.0.CO;2-Y     Document Type: Article

References (17)

1. Berger AR, Schaumburg HH, Schroeder C, Apfel S, Reynolds R: Dose response, coasting and differential fiber vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity. Neurology 1992;42:1367-1370.
2. Casey EB, Jellife AM, Quesne PML, Millett YL: Vincristine neuropathy. Clinical and electrophysiological observations. Brain 1973;96:69-86.
3. Coxon A, Pallis CA: Metronidazole neuropathy. J Naurol Neurosurg Psychiatry 1976;39:403-405.
4. Du RM, Dalakas M, Yarchoan Y, Broder S: Follow-up of neuropathy from 2′,3′-dideoxycytidine. Lancet 1995;
5. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL: Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992;10:1748-1753.
6. Hilkens PHE, Verweij J, Stoter G, Vecht CJ, Van Putten WLJ, Van den Bent MJ: Peripheral neurotoxicity induced by docetaxel. Neurology 1996;46:104-108.
7. Hovestadt A, Van der Burg MEL, Verbiest HBC, Van Putten WLJ, Vecht CJ: The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo. J Neural 1992;239:143-146.
8. Lipton RB, Apfel SC, Dutcher JP, Rosenberg R, Kaplan J, Berger A. Einzig AI, Werinik P, Schaumburg HH: Taxol produces a predominantly sensory neuropathy. Neurology 1989;39:368-373.
9. Masurovsky EB, Peterson ER, Grain SM, Horwitz SB: Microtubule arrays in taxol-treated mouse dorsal root ganglion-spinal cord cultures. Brain Res 1981;217:392-398.
10. New PZ, Jackson CE, Rinaldi D, Burris H, Barohn RJ: Neurotoxicity of docetaxel (taxotere). Neurology 1996;46:108-111.
11. Postma TJ, Vermorken JB, Liefting AJM, Pinedo HM, Heimans JJ: Paclitaxel-induced neuropathy. Ann Oncol 1995;6:489-494.
12. Roytta M, Raine CS: Taxol-induced neuropathy: chronic effects of local injection. J Neurocytol 1986;15:483-496.
13. Sahenk Z, Barohn R, New P, Mendell JR: Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neural 1994;51:726-729.
14. Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo DO, Ognibene FP, Cunnion RE, Reed E: Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992;10:1165-1170.
15. Van Genen JMA, Moll JWB, Van den Bent MJ, Bontenbal M, Van der Burg MEL, Verweij J, Vecht CJ: Paclitaxel (Taxol) induces cumulative mild neurotoxicity. Eur J Cancer 1994;30A:1074-1077.
16. Wernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP: Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987;5:1232-1239.
17. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E: Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987;47:2486-2493.